One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

Status Recruiting

Clinical Trial Summary

This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.

Clinical Trial Description

Latent tuberculosis infection (LTBI) or inactive tuberculosis, is a common disease found in patients with end-stage renal disease (ESRD) who are being considered for renal transplant (RT). Approximately 5-15% of patients with LTBI will convert to an active form of TB, especially in patients with a weak immune system. Given the morbidity and mortality associated with active TB disease along with the public health threat, LTBI is routinely treated in pre-transplant candidates. While treatment with isoniazid (INH) for 9 months is the mainstay of therapy, its use poses some clinical challenges due to the prolonged duration of treatment, risk of adverse drug effects, and suboptimal compliance and treatment completion. In addition to these challenges, the consequences of delays in transplant due to the time it takes to complete current treatment options are notable. Most recently, there is a large international, randomized, prospective, phase 3 clinical trial by Swindell et al., that found that 1 month of INH and Rifapentine (1m-INH-RPT) compared to the standard 9-month regimen of INH in HIV patients with LTBI had similar TB incidence in both treatment arms but higher compliance rate and fewer adverse events for patients taking 1m-INH-RPT. Given these findings, if a similar study can be conducted in renal transplant candidate population, it can alleviate the aforementioned challenges being faced in RT candidates. Thus, this is a single-arm, open-label, prospective clinical trial investigating the safety, compliance, pharmacokinetics of 1m-INH-RPT in RT candidates. ;

Study Design

Related Conditions & MeSH terms

End Stage Renal Disease
Kidney Diseases
Kidney Failure, Chronic
Latent Tuberculosis
Renal Transplant Candidate for Left Kidney
Renal Transplant Candidate for Right Kidney
Tuberculosis

Clinical Trial Details

NCT number	NCT05411744
Study type	Interventional
Source	Rutgers, The State University of New Jersey
Contact	Pinki J Bhatt, MD
Phone	7329392610
Email	pb518@rwjms.rutgers.edu
Status	Recruiting
Phase	Phase 4
Start date	July 1, 2022
Completion date	June 30, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04076488` - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases	N/A
Completed	`NCT03289650` - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus	Phase 3
Completed	`NCT04042324` - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients	Phase 1/Phase 2
Completed	`NCT01242904` - Use of a Bimodal Solution for Peritoneal Dialysis	Phase 2
Active, not recruiting	`NCT03183245` - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis	Phase 3
Completed	`NCT03257410` - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients	N/A
Completed	`NCT03627299` - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors	Phase 4
Recruiting	`NCT05917795` - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates	N/A
Terminated	`NCT03539861` - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients	N/A
Withdrawn	`NCT02130817` - Belatacept in Kidney Transplantation of Moderately Sensitized Patients	Phase 4
Completed	`NCT05540457` - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)	N/A
Not yet recruiting	`NCT04900610` - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis	N/A
Recruiting	`NCT02176434` - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease	N/A
Active, not recruiting	`NCT02581449` - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis	Phase 2
Completed	`NCT02830490` - Reliability of Functional Measures in Hemodialysis Patient.	N/A
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Completed	`NCT02832440` - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis	N/A
Completed	`NCT02832466` - Quantifying the Deterioration of Physical Function in Renal Patients	N/A
Completed	`NCT02215655` - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence	N/A
Recruiting	`NCT01912001` - Virtual Ward for Home Dialysis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.